A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · HEALTH SERVICES RESEARCH · NONE
- Evidence population
- Human clinical study registration
- Participants
- 109
- Population
- ALL · 50 Years to 95 Years
- Duration
- 2014-11-23 to 2016-12-29
- Intervention
- Bevacizumab
- Comparator
- IVIBx1; IVIBx2
- Outcomes measured
- comparison of the mean modifications of the maximal visual acuity (BCVA, Best-Corrected Visual Acuity) between the IVIB…; comparison of the number of intra-vitreous injections of bevacizumab (IVIB) between the IVIBx1 study group with respect…; comparison of the number of non-severe adverse events (NSAE) between the IVIBx1 study group with respect to those regis…; comparison of the number of severe adverse events (SAE) between the IVIBx1 study group with respect to those registered…; comparison of the number of unjustified absences of patients at the diagnostic checks and/or therapeutic procedures bet…; comparison of the mean modifications of the score of the National Eye Institute Visual Functioning Questionnaire (NEI-V…; comparison of the mean modification of the score of a specific questionnaire about patient's satisfaction for the recei…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.
